D2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendothelioma

[1]  M. Mihm,et al.  Infantile hemangiomas are arrested in an early developmental vascular differentiation state , 2004, Modern Pathology.

[2]  E. Kaiserling.  [Immunohistochemical identification of lymph vessels with D2-40 in diagnostic pathology]. , 2004, Der Pathologe.

[3]  E. Kaiserling.  Immunhistochemische Darstellung von Lymphgefäßen mit D2–40 in der diagnostischen Pathologie , 2004, Der Pathologe.

[4]  D. Jackson,et al.  Expression of a lymphatic endothelial cell marker in benign and malignant vascular tumors. , 2004, Human pathology.

[5]  Alexander Marks,et al.  Hobnail hemangiomas (targetoid hemosiderotic hemangiomas) are true lymphangiomas , 2004, Journal of cutaneous pathology.

[6]  A. Folpe,et al.  Kaposiform Hemangioendothelioma: A Study of 33 Cases Emphasizing Its Pathologic, Immunophenotypic, and Biologic Uniqueness From Juvenile Hemangioma , 2004, The American journal of surgical pathology.

[7]  R. Gausas,et al.  Proliferation of D2-40-expressing intestinal lymphatic vessels in the lamina propria in inflammatory bowel disease. , 2004, International journal of molecular medicine.

[8]  M. Skobe,et al.  Molecular characterization of lymphatic endothelial cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Alexander Marks,et al.  A New Monoclonal Antibody, D2-40, for Detection of Lymphatic Invasion in Primary Tumors , 2002, Laboratory Investigation.

[10]  Alexander Marks,et al.  Monoclonal Antibody D2-40, a New Marker of Lymphatic Endothelium, Reacts with Kaposi's Sarcoma and a Subset of Angiosarcomas , 2002, Modern Pathology.

[11]  R. Jain,et al.  LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. , 2001, Cancer Research.

[12]  S. Kumta,et al.  Kaposiform Hemangioendothelioma: Five Patients with Cutaneous Lesion and Long Follow-Up , 2001, Modern Pathology.

[13]  E. Mindell.  Enzinger and Weiss’s Soft Tissue Tumors. 4th ed. , 2001 .

[14]  A. Folpe,et al.  Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3): A Marker of Vascular Tumors with Presumed Lymphatic Differentiation, Including Kaposi's Sarcoma, Kaposiform and Dabska-Type Hemangioendotheliomas, and a Subset of Angiosarcomas , 2000, Modern Pathology.

[15]  Odile Enjolrasa,et al.  Residual lesions after Kasabach-Merritt phenomenon in 41 patients. , 2000 .

[16]  K. Alitalo,et al.  Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors , 1999, Cancer.

[17]  M. Karkkainen,et al.  Vascular endothelial growth factor-C: a growth factor for lymphatic and blood vascular endothelial cells. , 1998, Trends in cardiovascular medicine.

[18]  E. Tschachler,et al.  Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. , 1998, Cancer research.

[19]  I. Frieden,et al.  Kaposiform hemangioendothelioma : An aggressive, locally invasive vascular tumor that can mimic hemangioma of infancy , 1997 .

[20]  J. Mulliken,et al.  Thrombocytopenic Coagulopathy (Kasabach‐Merritt Phenomenon) Is Associated with Kaposiform Hemangioendothelioma and Not with Common Infantile Hemangioma , 1997, Plastic and reconstructive surgery.

[21]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  N. Skakkebaek,et al.  Expression of immunohistochemical markers for testicular carcinoma in situ by normal human fetal germ cells. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[23]  S. Weiss,et al.  Kaposiform Hemangioendothelioma of Infancy and Childhood: An Aggressive Neoplasm Associated with Kasabach-Merritt Syndrome and Lymphangiomatosis , 1993, The American journal of surgical pathology.

[24]  J. N. Schullinger.  Interferon alfa-2a therapy for life-threatening hemangiomas of infancy , 1992 .

[25]  J. Mulliken,et al.  Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy , 1992, The New England journal of medicine.

[26]  N. Skakkebaek,et al.  A novel maturation marker for human Sertoli cells. , 1989, International journal of andrology.

[27]  K. Carraway,et al.  O‐glycosylation pathway for mucin‐type glycoproteins , 1989, BioEssays : news and reviews in molecular, cellular and developmental biology.

[28]  H. Kahn,et al.  Production of a monoclonal antibody specific for seminomas and dysgerminomas. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Xiaowei Xu,et al.  Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix , 2005, Modern Pathology.

[30]  L. Litzky,et al.  Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma , 2005, Modern Pathology.

[31]  D. Elder,et al.  “D2-40 Immunoreactivity in Spindle Cell Tumors, a Specific Lymphatic Endothelial Marker?” , 2004 .

[32]  M. Mihm,et al.  GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. , 2000, Human pathology.

[33]  J. Mulliken,et al.  Residual lesions after Kasabach-Merritt phenomenon in 41 patients. , 2000, Journal of the American Academy of Dermatology.

[34]  J. Mulliken,et al.  Vascular tumors and vascular malformations (new issues). , 1997, Advances in dermatology.

[35]  H. Yeger,et al.  Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours , 1999, British Journal of Cancer.